Diagnosis-AHDX Dataset in Inhaled Nitric Oxide Use in Pediatric Intensive Care

This file includes the type of acquired heart disease diagnosed
Study Description
Acute lung injury (ALI) occurs in approximately 9% of mechanically ventilated children with 80% progressing to acute respiratory distress syndrome (ARDS). Inhaled nitric oxide (iNO) is an important therapy for neonates with persistent pulmonary hypertension, older children with pulmonary hypertension, and patients with congenital heart disease. It is hypothesized that iNO should benefit patients with ALI/ARDS by improving oxygenation. With this prospective observational trial, we found that clinician responsiveness to improved oxygenation was associated with less ventilator days. Algorithms to standardize ventilator management may improve signal to noise ratios in future trials enabling better assessment of the effect of inhaled nitric oxide on patient outcomes. Additionally, confining studies to more selective patient populations, such as those with right ventricular dysfunction, may be required. Subjects less than 18 years of age who were mechanically ventilated and received inhaled nitric oxide (iNO) in the PICU or CICU

本文件包含确诊的获得性心脏病类型。
研究描述
急性肺损伤（Acute Lung Injury, ALI）在接受机械通气的儿童中发生率约为9%，其中80%会进展为急性呼吸窘迫综合征（Acute Respiratory Distress Syndrome, ARDS）。
吸入性一氧化氮（Inhaled Nitric Oxide, iNO）是治疗持续性肺动脉高压新生儿、合并肺动脉高压的年长儿童以及先天性心脏病患者的重要疗法。
有假说提出，吸入性一氧化氮可通过改善氧合状态使急性肺损伤/急性呼吸窘迫综合征患者获益。
基于此项前瞻性观察性研究，我们发现临床医师对氧合改善的响应与更短的机械通气天数相关。
标准化机械通气管理的算法可优化未来试验中的信噪比，从而更精准地评估吸入性一氧化氮对患者临床结局的影响。
此外，未来研究或需将受试者限定为更具针对性的人群，例如合并右心室功能障碍的患者。
本研究的对象为年龄小于18岁、在儿科重症监护室（Pediatric Intensive Care Unit, PICU）或心脏重症监护室（Cardiac Intensive Care Unit, CICU）接受机械通气并接受吸入性一氧化氮治疗的受试者。